Evidence map›Paper›PMID 36296690›Full record

ArticleMolecules (Basel, Switzerland)2022

Copper(II) Complex Containing 4-Fluorophenoxyacetic Acid Hydrazide and 1,10-Phenanthroline: A Prostate Cancer Cell-Selective and Low-Toxic Copper(II) Compound.

Nayara Júnia de Souza Bontempo, Drielly Aparecida Paixão, Paula Marynella Alves Pereira Lima, Deysse Carla Tolentino Barros, Dayanne Silva Borges, Priscila Capelari Orsolin, Isabella Castro Martins, Pedro Henrique Alves Machado, Ricardo Campos Lino, Tiago Rodrigues de Souza and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Nayara Júnia de Souza BontempoInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Drielly Aparecida PaixãoInstituto de Química, Universidade Federal de Uberlândia, Uberlandia 38400-089, Brazil.
Paula Marynella Alves Pereira LimaInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Deysse Carla Tolentino BarrosInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Dayanne Silva BorgesInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Priscila Capelari OrsolinLaboratory of Cytogenetic and Mutagenesis, Centro Universitário de Patos de Minas, Patos de Minas 38700-207, Brazil.
Isabella Castro MartinsInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Pedro Henrique Alves MachadoInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Ricardo Campos LinoInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Tiago Rodrigues de SouzaInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Luana Munique Sousa RamosInstituto de Química, Universidade Federal de Uberlândia, Uberlandia 38400-089, Brazil.
Samuel Cota TeixeiraInstituto de Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlandia 38405-318, Brazil.ORCID 0000-0002-1978-1658
Raoni Pais SiqueiraInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Luiz Ricardo Goulart FilhoInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.
Wendell GuerraInstituto de Química, Universidade Federal de Uberlândia, Uberlandia 38400-089, Brazil.
Robson José de Oliveira JúniorInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.ORCID 0000-0001-8453-3194
Thaise Gonçalves de AraújoInstituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia 38400-902, Brazil.ORCID 0000-0002-7593-1403
Universidade Federal de Uberlândia · BRCentro Universitário de Patos de Minas · BR

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 0Federal University of Uberlândia 0Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01087-21 and APQ-00760-18National Council for Scientific and Technological Development 303210/2021-4National Institute of Science and Technology in Theranostics and Nanobiotechnology - INCT - Teranano 0
6 · The paper itself

Abstract

Prostate Cancer (PCa) is the second leading cause of cancer-related deaths among men worldwide. The treatment of advanced cases is based on chemotherapy, which lacks specificity and efficacy, due to severe side effects and resistance to the traditional drugs. Copper complexes have shown antitumoral efficacy and low toxicity, being considered a promising class of metal-based drugs for the treatment of malignant neoplasms. Thus, the present study aimed to evaluate the cellular effects of a copper(II) complex with 4-fluorophenoxyacetic acid hydrazide and 1,10-phenanthroline (

Indexed as

Antineoplastic AgentsProstatic NeoplasmsAndrogensAnimalsCarcinogenesisCell Line, TumorCopperCyclin D1DNA-Binding ProteinsDoxorubicinDrosophila melanogasterDrosophila ProteinsHumansHydrazinesKi-67 AntigenMale1,10-phenanthrolineAndrogensAntineoplastic AgentsCopperCyclin D1DNA-Binding ProteinsDoxorubicinDrosophila ProteinsHydrazinesKi-67 AntigenMutagensNerve Tissue ProteinsPhenanthrolinespnt protein, DrosophilaProto-Oncogene ProteinsTranscription Factorscell proliferationchemotherapycopper(II) complexesDrosophila melanogasterprostate cancer

Identifiers

PMID36296690
PMCPMC9609220
OpenAlexW4306936962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.